Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma

Hussein A Tawbi , Dirk Schadendorf , Evan J. Lipson , Hussein A Tawbi , Dirk Schadendorf , Evan J. Lipson , Paolo A. Ascierto , Luis Matamala , Erika Castillo Gutiérrez , Piotr Rutkowski , Helen J. Gogas , Christopher D. Lao , Juliana Janoski De Menezes , Stephane Dalle , Ana Arance , Jean-Jacques Grob , Shivani Srivastava , Mena Abaskharoun , Melissa Hamilton , Sarah Keidel , Katy L. Simonsen , Anne Marie Sobiesk , Bin Li , F. Stephen Hodi , Georgina V Long
2022 New England Journal of Medicine 1,530 citations

Abstract

The inhibition of two immune checkpoints, LAG-3 and PD-1, provided a greater benefit with regard to progression-free survival than inhibition of PD-1 alone in patients with previously untreated metastatic or unresectable melanoma. Relatlimab and nivolumab in combination showed no new safety signals. (Funded by Bristol Myers Squibb; RELATIVITY-047 ClinicalTrials.gov number, NCT03470922.).

MeSH Terms

AdultAgedAged80 and overAntibodiesMonoclonalHumanizedAntigensCDAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenDouble-Blind MethodFemaleHumansImmune Checkpoint InhibitorsMaleMelanomaMiddle AgedNivolumabProgression-Free SurvivalLymphocyte Activation Gene 3 Protein

Affiliated Institutions

Related Publications

Publication Info

Year
2022
Type
article
Volume
386
Issue
1
Pages
24-34
Citations
1530
Access
Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1530
OpenAlex
89
Influential
1457
CrossRef

Cite This

Hussein A Tawbi, Dirk Schadendorf, Evan J. Lipson et al. (2022). Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. New England Journal of Medicine , 386 (1) , 24-34. https://doi.org/10.1056/nejmoa2109970

Identifiers

DOI
10.1056/nejmoa2109970
PMID
34986285
PMCID
PMC9844513

Data Quality

Data completeness: 86%